TOURMALINE-MM1 is a phase III, randomized, double-blind, placebo-controlled study of ixazomib plus lenalidomide and dexamethasone (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma following 1-3 prior lines of therapy. The study met its primary endpoint, demonstrating significantly longer progression-free survival (PFS) in the IRd arm versus placebo-Rd arm (median 20.6 vs 14.7 months, hazard ratio 0.74, P 5 .01), with limited additional toxicity. Patientreported health-related quality of life (HRQoL) was a secondary endpoint of TOURMALINE-MM1.
| I N T R O D U C T I O N
Ixazomib, the first oral proteasome inhibitor, has been approved in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy in more than 40 countries, including the US, EU, Canada, and Japan. 1, 2 Ixazomib approval was based on the findings of the global, phase III, randomized, double-blind, placebo-controlled TOURMALINE-MM1 study (ClinicalTrials.gov identifier: NCT01564537), which compared the efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) versus placebo-Rd in adult patients with relapsed/refractory MM. 3 At the first prespecified interim analysis, after a median follow-up of 15 months, the primary endpoint of the study was met: progression-free survival (PFS) was improved by 35% with IRd versus placebo-Rd (hazard ratio of 0.74, P 5 .01), representing a 5.9-month improvement in median PFS (median 20.6 vs 14.7 months). A subsequent analysis was conducted after a median follow-up of 23 months to assess overall survival (OS) and safety. Median OS had not been reached in either study group at the time of this second analysis (only 24% of patients had died), and safety data demonstrated that IRd was associated with limited additional toxicity compared to placebo-Rd. 3 MM is an incurable, relapsing disease with a median age of 69 years at diagnosis. 4 MM significantly affects patient health-related quality of life (HRQoL), 5, 6 with reduced physical functioning, fatigue, and pain among the most common and problematic symptoms at diagnosis 7 ; other disease-related symptoms and treatment-related side effects can also have a substantial impact on HRQoL in MM patients. 6, 8, 9 Advances in MM treatment over the past 15 years have been associated with improvements in long-term outcomes, 10 and this has led to an increasing focus on continuous treatment approaches in MM, 11 with the aim of prolonging disease control and potentially providing a future cure for some patients. At the same time, patient HRQoL has become an increasingly important consideration when choosing therapy, 8 with patient-reported outcomes providing a growing contribution toward treatment decisionmaking. 12, 13 To assess any effect of study attrition on the estimate of treatment differences, a sensitivity analysis was performed on change from baseline in GHS/QoL score using a pattern mixture model to incorporate information on patterns of missing data. Assuming intermittent missing data occurred at random, patients were classified into two pattern groups: an early dropout group defined as dropout before 15 cycles, and a late dropout group defined as dropout 15 cycles.
The minimally important difference (MID) for the EORTC QLQ-C30
and QLQ-MY20 has been identified as 10 points for MM patients. 22 Numbers and proportions of patients achieving MID improvements from baseline were summarized descriptively; an additional analysis was performed using a MID of 5 points. and placebo-Rd, respectively, with 48% and 43% of patients having received 18 cycles. 3 At data cut-off, 62% and 63% of patients had discontinued IRd and placebo-Rd therapy, respectively, primarily due to PD in 34% and 40% of patients and due to adverse events in 17% and 14% of patients, respectively (Supporting Information Figure S1 ). 
| Changes in HRQoL during treatment
As reported in the TOURMALINE-MM1 primary publication, 3 EORTC QLQ-C30 GHS/QoL mean scores were maintained from baseline over the course of treatment in both the IRd and placebo-Rd groups (Supporting Information Figure S2A ). Similarly, as previously reported, in the linear mixed model analysis of change from baseline in EORTC QLQ-C30 GHS/ QoL score, similar results were seen between the IRd and placebo-Rd arms over time, with no statistically significant differences between the mean change from baseline scores at any of the time points; throughout the study, these changes were less than the MID of 10, thus QoL was largely unchanged (Supporting Information Figure S2B ). In the pattern mixture models conducted as a sensitivity analysis for missing data, although the individual cycle estimates differed slightly across the two pattern groups, this difference was not statistically significant or clinically meaningful (data not shown); the overall trend appears to be similar to that from the linear mixed model. Exploratory subgroup analyses were performed for selected subscales, with no differences reported (data not shown).
The 
| DISCUSSION
Despite the introduction of multiple novel agents and combination regimens, myeloma remains incurable with standard treatments; the goal of therapy is to delay disease progression and prolong OS. 24 As treatment paradigms are shifting toward continuous therapy [25] [26] [27] [28] [29] [30] to extend disease control and achieve better long-term outcomes, patients will increasingly be offered long-term therapy. In this context, maintaining patients' HRQoL during treatment will be key.
The present analyses demonstrate clearly that addition of the oral open-label, randomized phase III trials; [14] [15] [16] [17] 23 Additionally, the measurement of the general GHS score based on two questions alone could be particularly prone to this type of bias. For example, in openlabel data for carfilzomib in combination with Rd, an improvement in GHS score was reported; however, this improvement was not detected in any of the measured functional or symptom subscales. 23 Another consideration when assessing data from different studies is that differences between study populations may influence HRQoL outcomes, since it has been shown that baseline characteristics can impact
HRQoL over the course of treatment in MM. 9 For this study, exploratory subgroup analyses were performed for selected subscales, with no differences reported. Nevertheless, our data regarding HRQoL with placebo-Rd appear broadly consistent with data from other studies. For example, EORTC QLQ-C30 GHS/QoL scores for patients with relapsed MM were recently reported to be maintained from baseline over 18 cycles of open-label therapy with Rd. 23 Similarly, in the frontline setting, after an initial improvement, EORTC QLQ-C30 GHS/QoL scores were maintained through continued Rd treatment. 15 We note that the questions currently included in the HRQoL assessments may not be sensitive enough to pick up variations in HRQoL depending on the type of treatment administered. Additionally, although the tools available for HRQoL assessment in MM are validated and are consistent across studies, they may not be powerful enough to capture the intricacies and the real impact of treatment on patients' HRQoL. Studies suggest that existing questionnaires do not capture all that is important to patients and therefore may not be well suited to clinical use. 40, 41 Results from TOURMALINE-MM1 showed that adverse events reported with IRd were not substantially increased versus placebo-Rd: 
